Across TCGA pan-cancer cohorts, AMER1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AMER1 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AMER1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AMER1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where AMER1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.182	0.832	.045	6	view →
LUAD	DFS	Tertile	All	0.971	0.458	.043	3	view →
PDAC	OS	Median	II,III,IV	0.368	0.610	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: AMER1 tumor-vs-normal RNA expression · all AMER1 data types